- Home
- RMCF vs DYAI Comparison
RMCF vs DYAI Comparison
Compare RMCF & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMCF | DYAI |
|---|---|---|
| Founded | 1981 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.2M | 32.5M |
| IPO Year | 2024 | 2003 |
Fundamental Metrics
Financial Performance| Metric | RMCF | DYAI |
|---|---|---|
| Price | $1.68 | $0.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 38.4K | ★ 254.9K |
| Earning Date | 06-16-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.88 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,432,352.00 | $3,090,345.00 |
| Revenue This Year | N/A | $122.79 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.17 | $0.65 |
| 52 Week High | $2.99 | $1.35 |
Technical Indicators
Market Signals| Indicator | RMCF | DYAI |
|---|---|---|
| Relative Strength Index (RSI) | 29.64 | 41.87 |
| Support Level | $1.48 | N/A |
| Resistance Level | $1.82 | $1.00 |
| Average True Range (ATR) | 0.13 | 0.06 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 11.23 | 12.62 |
Price Performance
Historical ComparisonAbout RMCF Rocky Mountain Chocolate Factory Inc.
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, U-Swirl Operations, and Other t. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
About DYAI Dyadic International Inc.
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.